Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal
Stock Performance (Sep 2025) On Sept 30, 2025 Pfizer closed around $24.40 reuters.com. Over the past year PFE underperformed the pharma sector (latest 52-week range ~$20.91–30.43 reuters.com). Its trailing P/E is 12.64× reuters.com (ex. special items) and forward P/E ~7.7× reuters.com, compared to ~19× for J&J and ~12× for Merck (see table). Pfizer’s dividend yield (~7.2%) reuters.com is by far the highest in big pharma (JNJ ~2.9%, MRK ~4.1%). The stock rallied on strong earnings in early August s206.q4cdn.com reuters.com and on the Sept 30 Trump pricing news. Q2 2025 Financial Results and Corporate Updates Pfizer reported Q2 2025 revenue